Genmab Forms Third Antibody-Drug Conjugate Pact with Seattle Genetics
By Heather Cartwright
Pharma Deals Review: Vol 2014 Issue 10 (Table of Contents)
Published: 11 Oct-2014
DOI: 10.3833/pdr.v2014.i10.2067 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
In their latest antibody-drug conjugate (ADC) partnership, Genmab has gained rights to utilise Seattle Genetics’ auristatin-based ADC technology with HuMax®-AXL, a preclinical-stage antibody targeting the AXL receptor tyrosine kinase...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS